drugset / Trial / NCT00235989
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.
Timeline
- Start
- 2003-06
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon beta-1b | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | Interferon beta-1b | Protein / enzyme biologic | 500 ug | Subcutaneous |